ArticleWorld journal of surgical oncology2025
Limited benefit of adjuvant chemotherapy for Asian patients with stage IB lung adenocarcinoma: implications for clinical practice.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroudThe benefit of adjuvant chemotherapy for patients with stage IB lung adenocarcinoma remains unclear. We compared adjuvant chemotherapy outcomes in Asian and non-Asian stage IB lung adenocarcinoma patients using multi-source clinical data.
methodsPatients with stage IB lung adenocarcinoma from the 2004–2015 Surveillance, Epidemiology, and End Results (SEER) database and the 2020–2021 thoracic surgery department of three Chinese medical centers were included. Patients were divided into adjuvant chemotherapy and observation groups. Propensity score matching (PSM) was performed to reduce confounding bias. Survival curves were plotted and compared using the Kaplan–Meier method and log-rank test, respectively.
resultsIn the SEER data, 3408 patients met the inclusion criteria, overall survival (OS) was significantly better in the adjuvant chemotherapy group than in the observation group. In the non-Asian population, OS was significantly better in the adjuvant chemotherapy group, both before and after PSM. In the Asian population, OS did not significantly differ between the two groups before or after PSM. Among 690 patients from the three centers, disease-free survival (DFS) and OS in the adjuvant chemotherapy group were not better than those in the observation group, before or after PSM and in patients with high pathological grade or visceral pleural infiltration (VPI).
conclusionsAdjuvant chemotherapy can significantly improve the prognosis of non-Asian patients with stage IB lung adenocarcinoma. In Asian patients, adjuvant chemotherapy does not improve prognosis, even in patients with high pathological grade or VPI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.